Inimmune
Company

Last deal

$22M

Amount

Series A

Stage

09.07.2020

Date

2

all rounds

$22.59M

Total amount

date founded

Financing round

General

About Company
Inimmune is a biotech company developing immunotherapeutics for various diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2016

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Founded in 2016, Inimmune is a biotechnology company based in Missoula, Montana. They specialize in the discovery and development of novel immunotherapeutics for allergy, autoimmunity, and cancer. Their expertise in synthetic and process chemistry, drug formulation, and immunology allows them to develop compounds that modulate the innate immune system. Inimmune's pipeline includes several compounds targeting Toll-like Receptors 4 and 7/8, with preclinical programs focused on critical patient needs such as food allergy, allergic rhinitis, autoimmunity, and topical cancer treatments. They also offer contract services in preclinical drug development. Inimmune collaborates closely with the Center for Translational Medicine at the University of Montana and various industry and academia partners to advance their research and development efforts.
Contacts
Similar Companies
1000
Immutep

Immutep

Immutep is a global biotechnology company developing immunotherapeutic products for the treatment of cancer and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Sydney NSW 2000, Australia

total rounds

5

total raised

$73.47M
Immunovo

Immunovo

Immunovo is a Dutch biotechnology company focused on developing immunotherapeutic drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

's-Hertogenbosch, Netherlands

total rounds

1
OSE Immunotherapeutics

OSE Immunotherapeutics

OSE Immunotherapeutics is a biotech company developing innovative treatments for cancer and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Pharmaceuticals

Location

Nantes, France

total rounds

7

total raised

$61.81M
MacroGenics

MacroGenics

MacroGenics is a biotech company that develops immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Rockville, MD, USA

total rounds

11

total raised

$275.92M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$22.59M

Money Raised

Their latest funding was raised on 09.07.2020. Their latest investor National Institute of Allergy and Infectious Diseases. Their latest round Series A

Two Bear Capital

Two Bear Capital

Two Bear Capital invests in early-stage companies with disruptive innovations in biotech, AI, and cybersecurity.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Whitefish, MT 59937, USA

count Of Investments

21
National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases

NIAID conducts research to prevent and treat infectious and allergic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Bethesda, MD, USA

count Of Investments

101

count Of Exists

3
National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious is a medical research agency that supports basic and applied research for allergic diseases.

count Of Investments

75

count Of Exists

3
Co-Investors
Investors
3
3

Number of lead investors

3

Number of investors

National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases

NIAID conducts research to prevent and treat infectious and allergic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Bethesda, MD, USA

count Of Investments

101

count Of Exists

3
National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious is a medical research agency that supports basic and applied research for allergic diseases.

count Of Investments

75

count Of Exists

3
Two Bear Capital

Two Bear Capital

Two Bear Capital invests in early-stage companies with disruptive innovations in biotech, AI, and cybersecurity.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Whitefish, MT 59937, USA

count Of Investments

21
Michael Goguen

Michael Goguen

Michael Goguen was previously a venture capitalist at Sequoia Capital, focusing on energy, internet and technology investments. Michael currently sits on the board of Clean Cell, Clickatell Inc, Infoblox, Litepoint, OpenDNS, LogLogic, Quantenna Communications, R2 Semiconductors, Synapsense, Think Finance and Tula. Prior to joining Sequoia Capital in 1996, Michael spent 10 years in various engineering, research, and product management roles at DEC, SynOptics and Centillion, and was a director of Engineering at Bay Networks (NT). Michael was also a Technical Chairman of the ATM Forum.

current job

Digital Equipment Corporation
Digital Equipment Corporation

organization founded

1

People

Founders
4
Kendal Ryter
Kendal Ryter

Kendal Ryter

Kendal Ryter is a VP Product Development at Inimmune Corp. He attended Montana State University-Bozeman.

current job

Inimmune
Inimmune

organization founded

1

Kendal Ryter

Jay T. Evans
Jay T. Evans

Jay T. Evans

Evans Jay is the President and CEO at Inimmune Corporation.He attended Oregon State University.

current job

Inimmune
Inimmune

organization founded

1

Jay T. Evans

David J. Burkhart
David J. Burkhart

David J. Burkhart

Dr. David Burkhart is the Chief Operating Officer and Co-Founder of Inimmune, while also overseeing the formulation science R&D team. Dr. Burkhart was an investigator with GlaxoSmithKline for nearly 8 years leading the formulation R&D team where he demonstrated a knack for innovation and project/team management which led to his promotion from his starting role as a Principal Scientist. Prior to his work with GSK, Dr. Burkhart was a Senior Scientist with the CMO Hollister-Stier labs in Spokane, Washington for two years where he gained invaluable experience in cGMP analytical and manufacturing. He has over 10 years of experience in the biotechnology and pharmaceutical industries with experience in project management, leadership, business development, and licensing with over 13 years experience in medicinal and analytical chemistry, formulation and drug delivery. David earned his Ph.D. in organic chemistry in 2002 from the University of Idaho and conducted research in oncology as a postdoctoral scientist at the University of Colorado, Boulder until 2005.

current job

Inimmune
Inimmune

organization founded

1

David J. Burkhart

Helene Bazin-Lee
Helene Bazin-Lee

Helene Bazin-Lee

Dr. Bazin-Lee is VP, Early Discovery and Co-Founder of Inimmune, serving as head of early discovery research programs. She has over 17 years of experience in the biotech and pharmaceutical industries including 14 years with Corixa/GlaxoSmithKline developing new synthetic immunomodulators and vaccine adjuvants, managing medicinal chemistry efforts and new adjuvant discovery projects. Dr. Bazin-Lee earned an M.Sc. in Chemical Engineering at the ENSCCF (France) and received her Ph.D. in Organic Chemistry from the University of Lyon I (France). She then completed a postdoctoral fellowship at the University of Iowa, focusing on the development of new synthetic methods for the synthesis of glycosaminoglycan building blocks. Dr. Bazin-Lee is a co-inventor on 15 patents.

current job

Inimmune
Inimmune

organization founded

1

Helene Bazin-Lee

Employee Profiles
4
Jay T. Evans

Jay T. Evans

Co-Founder ,President & CEO

Helene Bazin-Lee

Helene Bazin-Lee

Co-Founder & Vice President Early Discovery

David J. Burkhart

David J. Burkhart

Co-Founder & Chief Operating Officer

Kendal Ryter

Kendal Ryter

Co-Founder & VP Product Development

Activity

Recent News
3
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week